This study is looking at how well a device called BaroStim works for people with a type of heart failure called NYHA Class III Heart Failure. BaroStim is a small device implanted under the skin that helps regulate blood pressure. Researchers will use readings from another implanted device called CardioMems, which measures pressure in your lungs (pulmonary artery diastolic pressure), to help adjust the BaroStim device. The goal is to see if adjusting BaroStim based on these readings can improve your heart health. You might be able to join if you are 18-80 years old, have NYHA Class III Heart Failure with a weakened heart (LVEF<35%), and can take heart medications. The study will consider the treatment successful if there's an improvement in your walking ability (6 Minute Walk Test), blood pressure, or heart failure symptoms. The current status of this study is unclear.

Study design

This is a single-arm study, meaning all participants will receive the BaroStim intervention. It plans to enroll 15 participants.

What's involved

You would first have a CardioMems device implanted and receive 3 months of medication management. After that, a BaroStim device would be implanted, and you would have in-office visits for BaroStim adjustments and measurements for up to 1 year.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for 1 year after the BaroStim device is inserted.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.